(Adnkronos) - L'introduzione dell’anticropo dell’anticorpo monoclonale bispecifico blinatumomab nella prima linea di trattamento aumenta significativamente la sopravvivenza globale dei pazienti affetti da leucemia linfoblastica acuta (Lla) da linfociti B Ph- di nuova diagnosi. Sono i risultati dello studio clinico di Fase III E1910, recentemente pubblicati sul New England Journal of Medicine, presentati a Milano in un evento promosso da Amgen, che aprono la prospettiva di un nuovo standard di cura per adulti con diagnosi di Lla.
Category
🗞
NewsTranscript
00:00There are about 450 Italian adults affected by acute lymphoblastic leukemia, a high-mortality
00:10rapid blood tumor.
00:11Research and the development of new therapies are making great strides, as evidenced by
00:17the clinical studies of Phase 3 and 19-10, recently published in the New England Journal
00:23of Medicine.
00:24The study shows that in patients affected by acute lymphoblastic leukemia in negative
00:28adenopathy and without trace of detectable disease, after the initial treatment, the addition
00:33of the bispecific antibody, Blinatumumab, to the chemotherapy of consolidation significantly
00:38increases survival.
00:40The study that has recently been published in the New England Journal of Medicine is
00:45an extremely important study because it shows, in a randomized study, therefore with a
00:50group of comparison, that the addition of the bispecific monoclonal antibody, Blinatumumab,
00:56which is a form of immunotherapy, is also active in patients who have acute lymphoblastic
01:02leukemia, negative philadelphia of line B, which are negative even for minimal disease.
01:08So it is an extremely important step forward for the treatment of these patients, in the
01:14first line.
01:15The scope of the change to which immunotherapy has given way is allowing the clinic to look
01:20at a new goal in the adult population, that of healing.
01:24The goal today is healing.
01:27And it is wonderful to be able to affirm this thing even in adult patients.
01:34Today we employ patients up to 65 years old in research protocols and beyond, with the
01:41aim of bringing them to healing.
01:43Blinatumumab is the first immunotherapy developed with the BITE platform, Amgen's Bispecific
01:48T-Cell Engager.
01:50Amgen, in the development of this platform, has had an extremely innovative approach,
01:55based precisely on the unprecedented connection between biology and technology.
02:01It started, of course, with acute lymphoblastic leukemia, in the recidivist phase, refractory,
02:09and then advanced towards the earlier phases of the disease, going through the so-called
02:15minimal residual disease, that is, leukemic clones present in minimal quantity, but which
02:20inevitably lead to the clinical and hematological relapse of the patient, up to the development
02:28in the first line.